Spots Global Cancer Trial Database for rcc
Every month we try and update this database with for rcc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | NCT00176280 | Renal Cell Carc... | Leukine Dexamethasone | 18 Years - | University of Kentucky | |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | NCT06255223 | Renal Cell Carc... Radiotherapy Immune Checkpoi... | High-dose Radio... Low-dose Radiot... Anti-PD-1 monoc... | 18 Years - 80 Years | Jinling Hospital, China | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC | NCT03876925 | Renal Cell Canc... | CT053PTSA | 18 Years - 75 Years | Sunshine Lake Pharma Co., Ltd. | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | NCT05168436 | Renal Cell Carc... | 18 Years - | Bristol-Myers Squibb | ||
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | NCT02575222 | Clear Cell Rena... | Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | NCT01649180 | Renal Cell Carc... | Axitinib | 18 Years - | PrECOG, LLC. | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | NCT00609401 | Metastatic Dise... Renal Cell Carc... | Nexavar (Sorafe... IL-2 | 18 Years - | Italian Trial in Medical Oncology | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | NCT04919122 | Metastatic Rena... | 19 Years - | Duke University | ||
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | NCT05168436 | Renal Cell Carc... | 18 Years - | Bristol-Myers Squibb | ||
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | NCT06158958 | Solid Tumors | ABBV-303 Budigalimab | 18 Years - | AbbVie | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy | NCT03891485 | RCC Metastatic Rena... | Immunological a... | - | National Cancer Institute, Naples | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | NCT00113217 | Renal Cell Carc... Kidney Cancer | Bevacizumab | - | M.D. Anderson Cancer Center | |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | NCT04834778 | Renal Cell Carc... Gastric Cancer Metastatic Brea... Small-cell Lung... Other Solid Tum... | HC-5404-FU | 18 Years - | HiberCell, Inc. | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer | NCT00445523 | Carcinoma, Rena... | TroVax® (Immuno... Interferon-alph... | 18 Years - | The Methodist Hospital Research Institute | |
| Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | NCT00079612 | Carcinoma, Rena... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | NCT04919122 | Metastatic Rena... | 19 Years - | Duke University | ||
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | NCT05462873 | Carcinoma, Non-... Carcinoma, Rena... Esophageal Squa... Squamous Cell C... | QEQ278 | 18 Years - | Novartis | |
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | NCT00352859 | Carcinoma, Rena... | Nexavar (Sorafe... Gemcitabine or ... | 18 Years - | Bayer | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | NCT01582672 | Advanced Renal ... Renal Cell Carc... Metastatic Rena... | Standard Treatm... AGS-003 | 18 Years - | Argos Therapeutics | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | NCT03427476 | Renal Cell Carc... | CTT1057 | 18 Years - | Cancer Targeted Technology | |
| A Rollover Protocol for Subjects Previously Treated With AGS-003 | NCT01482949 | Renal Cell Carc... | AGS-003 | 18 Years - | Argos Therapeutics | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | NCT03176485 | Metastatic Canc... Melanoma Colon Cancer Differentiated ... Hepatocellular ... Renal Cell Carc... Metastatic Mela... HCC Metastatic Colo... | Solar Simulator | 18 Years - | University of Arizona | |
| Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | NCT01392183 | Kidney Cancer | Pazopanib Temsirolimus Quality of Life... Benadryl | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) | NCT05917106 | Carcinoma Renal Cell Carc... RCC Kidney Neoplasm... Kidney Cancer | - | Jinling Hospital, China | ||
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | NCT00467025 | Advanced Renal ... | AMG 386 Sorafenib AMG 386 placebo... | 18 Years - | Amgen | |
| To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors | NCT02410174 | Primary Tumor Renal Cell Carc... | Stereotactic Bo... | 18 Years - | Beth Israel Medical Center | |
| Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) | NCT00672178 | Renal Cell Carc... | Stereotactic bo... | 18 Years - 80 Years | Duke University | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | NCT00561912 | Renal Cell Carc... | Decitabine Interferon Alfa... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | NCT02771626 | Clear Cell Rena... Melanoma Non-small Cell ... | CB-839 Nivolumab | 18 Years - | Calithera Biosciences, Inc | |
| IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. | NCT01967407 | Kidney Tumor Renal Cell Canc... | Irreversible El... | 18 Years - | University of Magdeburg | |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC | NCT03876925 | Renal Cell Canc... | CT053PTSA | 18 Years - 75 Years | Sunshine Lake Pharma Co., Ltd. | |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | NCT06255223 | Renal Cell Carc... Radiotherapy Immune Checkpoi... | High-dose Radio... Low-dose Radiot... Anti-PD-1 monoc... | 18 Years - 80 Years | Jinling Hospital, China | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) | NCT05931393 | RCC Renal Cell Carc... | Cabozantinib 80... Cabozantinib 40... Nivolumab | 18 Years - | University of Texas Southwestern Medical Center | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| A Rollover Protocol for Subjects Previously Treated With AGS-003 | NCT01482949 | Renal Cell Carc... | AGS-003 | 18 Years - | Argos Therapeutics | |
| Zoledronate With Atorvastatin in Renal Cell Carcinoma | NCT00490698 | Kidney Cancer Renal Cell Carc... | Zoledronate Atorvastatin | - | M.D. Anderson Cancer Center | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma | NCT06376669 | Renal Cell Carc... | Proton Stereota... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pemetrexed Plus Gemcitabine in Renal Cell Cancer | NCT00491075 | Renal Cell Carc... | Pemetrexed Gemcitabine | - | M.D. Anderson Cancer Center | |
| Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | NCT01392183 | Kidney Cancer | Pazopanib Temsirolimus Quality of Life... Benadryl | 18 Years - | M.D. Anderson Cancer Center | |
| Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | NCT02560012 | Carcinoma, Rena... | Sunitinib Temsirolimus Sorafenib Pazopanib Everolimus Axitinib | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | NCT01297244 | Renal Cell Carc... | Tivozanib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma | NCT02399124 | Renal Cell Carc... | PROSENSE™ | 18 Years - | IceCure Medical Ltd. | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | NCT02315066 | Neoplasms | PF-04518600 PF-04518600 PF-04518600 plu... PF-04518600 plu... | 18 Years - | Pfizer | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
